Table 1 Baseline characteristics of patients^a with and without day 7 lumefantrine concentrations

Age (years)

2,786

6.2 (0.3 to 86.7)

2,805

5.5 (0.2 to 80.0)

0.028

Age category

<0.001

  < 1 year

82 (3.0)

107 (3.8)

 1–2 years

573 (20.6)

590 (21.0)

 3–4 years

615 (22.1)

604 (21.5)

 5–11 years

564 (20.2)

852 (30.4)

  ≥ 12 years

953 (34.2)

652 (23.2)

Weight (kg)

2,786

18.5 (5.0 to 150.0)

2,797

17.0 (5.0 to 97.0)

0.104

Underweight^c

1,269

220 (17.3)

1,299

218 (16.8)

0.211

Total dose (mg/kg)

2,764

65.5 (19.2 to 144.0)

2,786

65.5 (20.9 to 144)

0.092

Treatment supervision

2,787

2,788

<0.001

 Fully

1,971 (70.7)

1,644 (59.0)

 Partially

115 (4.1)

602 (21.6)

 Unsupervised

701 (25.2)

542 (19.4)

Co-administration with fat

2,787

2,809

0.147

Yes/advised

2,204 (79.1)

1,752 (62.4)

Not stated

583 (20.9)

1,057 (37.6)

Parasitemia (/μl)

2,767

17,140 (16 to 524,414)

2,799

18,120 (10 to 862,400)

0.021

Temperature (°C)

2,662

37.7 (34.3 to 41.9)

1,967

37.5 (35.0 to 41.5)

<0.001

Hemoglobin (g/dL)

2,068

10.6 (4.8 to 25)

1,484

11.3 (4.2 to 17.9)

0.428

Sex (female)

2,787

1,281 (46.0)

2,805

1,278 (45.6)

0.857

Gametocytes present

2,418

112 (4.9)

1,654

92 (5.6)

0.797

Moderate anemia

2,507

1,132 (45.1)

1,484

516 (34.8)

0.016

Severe anemia

2,507

155 (6.2)

1,484

57 (3.8)

0.056